Clinical Trials Logo

Recurrent Head and Neck Cancer clinical trials

View clinical trials related to Recurrent Head and Neck Cancer.

Filter by:

NCT ID: NCT03544723 Recruiting - Clinical trials for Recurrent Head and Neck Cancer

Safety and Efficacy of Ad-p53 in Head and Neck Cancer

Start date: June 5, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study of the combination of Ad-p53 administered intra-tumorally with Nivolumab in patients with recurrent head and neck squamous cell cancer and favorable p53 status. There are two cohorts, one with Ad-p53 in combination with Opdivo, one with Opdivo alone, in an unblinded design. General safety and efficacy using RECIST 1.1 and Immune-Related Response Criteria as well as ECOG numbers will be followed.

NCT ID: NCT02842125 Not yet recruiting - Clinical trials for Recurrent Head and Neck Cancer

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

Start date: August 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal carcinoma (CRC) and other solid tumors, including primary hepatocellular carcinoma (HCC). A third arm will study the intra-tumoral injection of Ad-p53 combined with nivolumab infusions in recurrent head and neck squamous cell cancer (HNSCC). This safety study has a standard 3+3 design for arms A and B; .HNSCC will be placed in a single dosing cohort. The Maximum Tolerated Dose (MTD) will be determined as well for intra-arterial infusions, and the entire study will determine the general efficacy using RECIST 1.1 and Immune-Related Response Criteria. Safety will be followed using the CTCAE listings for adverse events.

NCT ID: NCT02567383 Recruiting - Clinical trials for Recurrent Head and Neck Cancer

Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer

Start date: September 2015
Phase: Phase 2
Study type: Interventional

Clinical experience of with hyperthermia combined with radiotherapy and chemotherapy for recurrent head and neck cancer is limited. The primary goals of hyperthermia combined with CCRT on recurrent head and neck cancer are tumor response rate, while secondary goals are rates of acute and late adverse effects, local control rate, distant metastasis rate, progression-free rate and overall survival rate.

NCT ID: NCT02422979 Active, not recruiting - Clinical trials for Recurrent Head and Neck Cancer

Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer

Start date: June 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a two-part clinical study of patients with recurrent Head and Neck Cancer (HNC), who in the opinion of their physician, cannot be satisfactorily treated with surgery, radiation or platinum chemotherapy. The purpose of the study is to determine the safety and anti-cancer activity of various doses and repeated cycles of the experimental treatment using the study drug RM-1929 and fixed amounts of red light applied at the tumor site to activate the pharmacodynamics of the drug. The part 1 of the study has been completed and consisted in a single cycle, 3+3 dose escalation safety study of the experimental drug RM-1929 using a fixed amount of 690 nm red light. The part 1 was designed to determine the safety of the treatment as set by the maximal feasible dose or the maximal tolerable dose of RM-1929. From the part 1 results, the maximal feasible dose of RM-1929 was determined. The part 2 of the study is currently ongoing and it is evaluating the safety and anticancer efficacy of up to four repeated treatments of Photoimmunotherapy with RM-1929 at the maximal feasible dose of RM-1929 activated with a fixed amount of red light.

NCT ID: NCT02358031 Active, not recruiting - Clinical trials for Recurrent Head and Neck Cancer

A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Start date: March 19, 2015
Phase: Phase 3
Study type: Interventional

Participants with recurrent or metastatic (R/M) squamous cell cancer of the head and neck (HNSCC) will be randomly assigned to receive pembrolizumab alone, or pembrolizumab + a platinum-based drug (cisplatin or carboplatin) + 5-Fluorouracil (5-FU), or cetuximab + a platinum-based drug (cisplatin or carboplatin) + 5-FU. The primary study hypothesis is that pembrolizumab or pembrolizumab in combination with chemotherapy prolongs progression free survival and overall survival compared to standard treatment.

NCT ID: NCT02289209 Recruiting - Clinical trials for Carcinoma, Squamous Cell of Head and Neck

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Start date: December 2014
Phase: Phase 2
Study type: Interventional

Eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck will be treated with reirradiation combined with anti-PD-1 mAb MK-3475 (generic name: pembrolizumab, trade name Keytruda®).

NCT ID: NCT01620242 Completed - Clinical trials for Recurrent Head and Neck Cancer

A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes

ORL03
Start date: April 2012
Phase: Phase 2
Study type: Interventional

This is a multi-center phase II study assessing whether cabazitaxel could be efficient for treatment of recurrent or metastatic head and neck cancer after failure of cisplatin, cetuximab and taxanes.

NCT ID: NCT01606566 Terminated - Clinical trials for Carcinoma, Squamous Cell of Head and Neck

A Study to Evaluate the Safety and Efficacy of PC-A11 in Patients With Recurrent Head and Neck Squamous Cell Carcinoma

Start date: April 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of PC-A11 with superficial and/or interstitial laser light application in patients with recurrent SCCHN.

NCT ID: NCT01255800 Completed - Clinical trials for Recurrent Head and Neck Cancer

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer

Start date: April 2011
Phase: Phase 1
Study type: Interventional

This study will evaluate the clinical activity of the combination of ipilimumab (IPI) -926 in combination with cetuximab in patients with advanced head and neck cancer.

NCT ID: NCT00088907 Terminated - Clinical trials for Recurrent Head and Neck Cancer

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

Start date: August 2004
Phase: Phase 3
Study type: Interventional

Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining docetaxel with gefitinib may kill more tumor cells. It is not yet known whether docetaxel is more effective with or without gefitinib in treating head and neck cancer. This randomized phase III trial is studying docetaxel and gefitinib to see how well they work compared to docetaxel alone in treating patients with metastatic or locally recurrent head and neck cancer.